Actavis acquired a 51% controlling interest in ZiO Zdorovje, a Russian pharmaceutical manufacturer.
Out of a total cost of $60 million for the deal, $30 million will be targeted for investment in the ZiO Zdorovje manufacturing site with the goals of creating a platform for increased production and capacity as well as introducing new products.
The current owners of ZiO Zdorovje will retain a 49% stake in the business.